Prime Medicine Inc(PRME) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 6:14 AM ET (Korea 10/29 19:14)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.09 | Insider Own | 46.28% | Shs Outstand | 180.7M | Perf Week | 40.68% |
| Market Cap | 0.97B | Forward P/E | - | EPS next Y | 4.16% | Insider Trans | - | Shs Float | 97.4M | Perf Month | 73.46% |
| Enterprise Value | 0.99B | PEG | - | EPS next Q | -0.24 | Inst Own | 49.39% | Short Float | 33.74% | Perf Quarter | 77.48% |
| Income | -0.19B | P/S | 238.87 | EPS this Y | 28.53% | Inst Trans | 6.36% | Short Ratio | 9.05 | Perf Half Y | 51.84% |
| Sales | 0.00B | P/B | 24.33 | EPS next 5Y | 13.58% | ROA | -71.16% | Short Interest | 32.87M | Perf YTD | 54.47% |
| Book/sh | 0.22 | P/C | 10.23 | EPS past 3/5Y | 2.55% -91.28% | ROE | -373.29% | 52W High | 4.89% ($5.11) | Perf Year | 11.2% |
| Cash/sh | 0.52 | P/FCF | - | Sales past 3/5Y | - -2.32% | ROIC | -131.1% | 52W Low | 100.75% ($2.67) | Perf 3Y | -4.11% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 32.1% | Gross Margin | -81.64% | Volatility(W/M) | 15.41% 11.7% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 243.14 | Sales Y/Y TTM | -17.9% | Oper. Margin | -4824.94% | ATR (14) | 0.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.05 | EPS Q/Q | 41.64% | Profit Margin | -4613.11% | RSI (14) | 73.12 | Recom | 1.46 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.05 | Sales Q/Q | 3.5% | SMA20 | 45.71% ($3.68) | Beta | 2.34 | Target Price | $7.53 |
| Payout | - | Debt/Eq | 2.83 | Earnings | 2026/8/6 | SMA50 | 54.28% ($3.47) | Rel Volume | 4.18 | Prev Close | $4.35 |
| Employees | 146 | LT Debt/Eq | 2.6 | EPS/Sales Surpr. | 6.69% -48.74% | SMA200 | 53.75% ($3.49) | Avg Volume(3M) | 3.63M | Price | $5.36 |
| IPO | 2022/10/20 | Option/Short | Yes/Yes | Trades | 29999 | Volume | 15,200,949 | Change | 23.22% |
🧬 Prime Medicine (PRME) is a US biotechnology company developing a prime editing platform, a next-generation gene editing technology capable of editing across the entire genome. The company has secured technology that overcomes the limitations of conventional gene scissors by performing precise insertion, deletion, and substitution of genetic information without cutting the DNA double helix. Through research collaborations with numerous biotechnology companies, the company is pursuing new drug development and enhancing the value of its pipeline.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded more than usual. That is 418% of its average volume.
PRME has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +28.5% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $23,887. Peers typically go for $1,237.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be -4.1%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
33.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #159 of 594 in the industry
Based on market cap of $972M.
PRME#159 Prime Medicine Inc $972M PER - 
ORIC#160 ORIC Pharmaceuticals Inc $964M PER - 
KURA#161 Kura Oncology Inc $954M PER - 
ALMS#162 Alumis Inc $952M PER - 
RIGL#163 Rigel Pharmaceuticals $948M PER 3.1 
FAQ
What kind of company is PRME?
PRME belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PRME?
The market cap of PRME is approximately $972M, ranking 2,603 within its sector.
What is the 52-week high and low for PRME?
PRME has recorded a 52-week high of $5.11 and a low of $2.67.
